26 ± 18), although this change did not reach statistical significance (Wilcoxon signed-rank test).
← all excerpts
Effects of the continuous subcutaneous infusion of foslevodopa-foscarbidopa on swallowing in patients with Parkinson's disease.
2
—
—
The sentences
Changes in motor function as evaluated by the Hoehn–Yahr scale and UPDRS-III Motor function, as measured by the UPDRS-III, showed a trend toward improvement following the introduction of CSCI-FF (32 ± 22 vs. 26 ± 18), although this change did not reach statistical significance (Wilcoxon signed-rank test).